- Home
- ACC 2019: Duration Of Diabetes And Cardiorenal Efficacy Of Liraglutide And Semaglutide - Prof Subodh Verma
ACC 2019: Duration Of Diabetes And Cardiorenal Efficacy Of Liraglutide And Semaglutide - Prof Subodh Verma
Topic:
- Prevention
Available Credit:
- Not accredited
Course Published On:
Course Expiry Date:
Overview
Prof Subodh Verma (University of Toronto, Toronto, CA) discusses his poster presented at the ACC 2019 entitled duration of diabetes and cardiorenal efficacy of liraglutide and semaglutide - a post hoc analysis of the LEADER and SUSTAIN-6 Clinical Trials.
Target Audience
- Cardiologists
- Diabetologists
- Nephrologists
This course is not accredited
Related Courses
Advancements in Triglyceride-lowering Therapies
- 1.00
Published:
Learning objectives
- Recall the primary and secondary outcomes from key triglyceride-lowering trials presented during ESC 2024
- Discuss the current and future implication of trial results to clinical management and practice guidelines
Elevating Understanding and Management of Hypertriglyceridemia
- 1.25
Published:
Learning objectives
- Understand HTG as a risk factor for acute and chronic illness
- Describe current guideline directed management of HTG
- Recognise the gaps and challenges present in current guideline directed management of HTG
- Recall emerging trial data for novel pharmacological targets
- Use guidelines, trial data & expert opinion to develop individualised treatment strategies for high-risk patients
Hyperkalaemia in Cardiorenal Disease – A Case Based Discussion
- Not accredited
Published:
Learning objectives
- Explain the relationship between sub-optimal RAASi therapy and poor cardio-renal outcomes
- Identify patients who would benefit from anti-hyperkalaemia medications
- Select appropriate anti-hyperkalaemia treatments across a range of patient profiles
- Adopt anti-hyperkalaemia medications as an approach to prolong optimal RAASi therapy
- Summarise current guideline recommendations on the use of potassium binding agents
Examining a Complex Heart Failure Case
- 1.00
Published:
Learning objectives
- Identify individuals likely to have HFpEF from initial presentation
- Refer suspected individuals for specialist assessment
- Initiate GDMT for HF as soon as patients are stable
- Initiate GDMT in HF regardless of EF and phenotype
- Initiate shared decision-making on complex HF patients with other members of the multidisciplinary team including cardiologists, GPs, nephrologists and diabetologists
CVD and Type 2 Diabetes: Navigating Therapeutic Boundaries in GLP-1 RA Use
- 2.00
Published:
Learning objectives
- Describe the burden of ASCVD in type 2 diabetes
- Assign risk of future CV events to individuals with type 2 diabetes
- Identify appropriate patients for GLP-1 RA therapy based on clinical trial outcome data to reduce ASCVD risk
- Recall trial data of anti-diabetes medications that reduce ASCVD risk
- Recall the pleiotropic effects of GLP-1 RAs and how these may impact CV outcomes
- Describe how early adoption of anti-diabetes therapies with proven CV benefit can positively influence QOL
- Adopt anti-diabetic therapies with proven ASCVD benefit
Obstructive Hypertrophic Cardiomyopathy: Getting It Right First Time
- 1.00
Published:
Learning objectives
- Recall the general approach to diagnosis and stratification of HCM according to the latest guidelines and expert opinion
- Apply advanced echocardiographic methodologies to equivocal HCM diagnoses
- Select appropriate imaging modalities to facilitate accurate risk stratification
- Stratify patients based on specific risk features and disease severity
- Choose suitable treatment modalities for patients based on specific disease features and severity